amifostine anhydrous has been researched along with Body Weight in 31 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amifostine has been shown to be capable of minimizing radiotherapy-induced oral mucositis, but whether it protects small intestinal mucosae from high-dose methotrexate-induced damage is presently unknown." | 7.79 | Protective effect of amifostine on high-dose methotrexate-induced small intestinal mucositis in mice. ( Cao, X; Chen, C; Hao, L; Li, X; Liu, Q; Sun, Q; Tian, L; Zhang, M; Zhang, X, 2013) |
| "Amifostine has been shown to be capable of minimizing radiotherapy-induced oral mucositis, but whether it protects small intestinal mucosae from high-dose methotrexate-induced damage is presently unknown." | 3.79 | Protective effect of amifostine on high-dose methotrexate-induced small intestinal mucositis in mice. ( Cao, X; Chen, C; Hao, L; Li, X; Liu, Q; Sun, Q; Tian, L; Zhang, M; Zhang, X, 2013) |
| " However, amifostine did not protect young rats against the late toxic effect of doxoubicin on linear growth, body weight, plasma leptin levels, and heart or testicular tissue." | 3.71 | Amifostine protects against early but not late toxic effects of doxorubicin in infant rats. ( Eksborg, S; Jahnukainen, K; Jahnukainen, T; Salmi, TT; Söder, O; Svechnikov, K, 2001) |
| "Compared to dexrazoxane, amifostine provided a comparable degree of protection against the nephrotoxicity of doxorubicin, but was less cardioprotective and did not prevent the mortality and loss of body weight produced by doxorubicin." | 3.70 | Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats. ( Chadwick, DP; Ferrans, VJ; Herman, EH; Zhang, J, 2000) |
| " The lack of improved duration of response or impact on survival may be the result of the limited improvement of efficacy with the higher dosage of cisplatin in conjunction with WR-2721, or the limited number of patients accrued to this study." | 2.71 | Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686). ( Borden, E; Ewell, M; Glick, J; Glover, D; Ibrahim, J; Karp, D; Kirkwood, J; Stewart, J, 2003) |
| " Differential toxicity study of SM and HN-3 reveals that both the compounds were more toxic by percutaneous route as compared to subcutaneous route." | 1.36 | Ameliorative effect of DRDE 07 and its analogues on the systemic toxicity of sulphur mustard and nitrogen mustard in rabbit. ( Ganeshan, K; Gautam, A; Kumar, A; Kumar, P; Pathak, U; Prakash, CJ; Vijayaraghavan, R, 2010) |
| " In the search for more effective and less toxic antidotes, various combinations were tried against SM induced toxicity and skin lesions." | 1.36 | Prophylactic efficacy of combination of DRDE-07 and its analogues with amifostine against sulphur mustard induced systemic toxicity. ( Gautam, A; Gupta, A; Lomash, V; Pant, SC; Vijayaraghavan, R, 2010) |
| "Aminothiol amifostine (AMI) protects against toxic effects of both ionizing radiation and numerous anticancer drugs." | 1.32 | Amifostine protection against doxorubicin cardiotoxicity in rats. ( Bokonjic, DR; Dobric, SL; Dogovic, NP; Dragojevic-Simic, VM; Jacevic, VM; Sinovec, SM; Vucinic, ZM, 2004) |
| "Cysteamine treatment increased the development of ER-negative tumors." | 1.31 | Inhibitory effects of WR-2721 and cysteamine on tumor initiation in mammary glands of pregnant rats by radiation. ( Inano, H; Kobayashi, H; Onoda, M; Suzuki, K; Wakabayashi, K, 2000) |
| "After treatment, whole body weights and wet organ weights of liver, spleen, and kidney, as well as gross and histologic changes in these and other tissues, were monitored on Days 1, 4, 7, 11, 15, 21, and 28." | 1.28 | Histopathologic effects of soluble glucan and WR-2721, independently and combined in C3H/HeN mice. ( Baker, WH; Jackson, WE; Nold, JB; Patchen, ML, 1992) |
| " The 1/10 lethal dose in mice was slightly toxic to dogs; 1/10 of that dose was nontoxic." | 1.27 | Toxicity studies on the radioprotective agent WR-2721 in CDF1 mice and beagle dogs. ( Dickie, BC; Glaza, SM; Greenspun, KS; Palmer, TE; Weltman, RH, 1985) |
| " WR-2721 can, therefore, increase the effectiveness of cisplatin therapy through selective protection against the toxic side effects of chemotherapy." | 1.26 | Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum(II) by WR-2721 without altering its antitumor properties. ( Culo, F; Yuhas, JM, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (35.48) | 18.7374 |
| 1990's | 2 (6.45) | 18.2507 |
| 2000's | 13 (41.94) | 29.6817 |
| 2010's | 5 (16.13) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pan, J | 1 |
| He, H | 1 |
| Su, Y | 1 |
| Zheng, G | 1 |
| Wu, J | 1 |
| Liu, S | 1 |
| Rao, P | 1 |
| Chen, C | 1 |
| Tian, L | 1 |
| Zhang, M | 1 |
| Sun, Q | 1 |
| Zhang, X | 1 |
| Li, X | 2 |
| Cao, X | 1 |
| Liu, Q | 1 |
| Hao, L | 1 |
| Mihailović, M | 2 |
| Dobrić, S | 1 |
| Poznanović, G | 2 |
| Petrović, M | 1 |
| Uskoković, A | 1 |
| Arambasić, J | 1 |
| Bogojević, B | 1 |
| Sharma, M | 2 |
| Vijayaraghavan, R | 5 |
| Gautam, A | 3 |
| Milosević, V | 1 |
| Grigorov, I | 1 |
| Ivanović-Matić, S | 1 |
| Grdović, N | 1 |
| Bogojević, D | 1 |
| Kumar, P | 2 |
| Prakash, CJ | 1 |
| Kumar, A | 2 |
| Ganeshan, K | 1 |
| Pathak, U | 1 |
| Agrawal, OP | 1 |
| Gupta, A | 1 |
| Lomash, V | 1 |
| Pant, SC | 1 |
| Abushamaa, AM | 1 |
| Sporn, TA | 1 |
| Folz, RJ | 1 |
| Glover, D | 1 |
| Ibrahim, J | 1 |
| Kirkwood, J | 1 |
| Glick, J | 1 |
| Karp, D | 1 |
| Stewart, J | 1 |
| Ewell, M | 1 |
| Borden, E | 1 |
| Dragojevic-Simic, VM | 1 |
| Dobric, SL | 1 |
| Bokonjic, DR | 1 |
| Vucinic, ZM | 1 |
| Sinovec, SM | 1 |
| Jacevic, VM | 1 |
| Dogovic, NP | 1 |
| Damron, TA | 1 |
| Spadaro, JA | 1 |
| Horton, JA | 1 |
| Margulies, BS | 1 |
| Strauss, JA | 1 |
| Farnum, CE | 1 |
| Rolleman, EJ | 1 |
| Forrer, F | 1 |
| Bernard, B | 1 |
| Bijster, M | 1 |
| Vermeij, M | 1 |
| Valkema, R | 1 |
| Krenning, EP | 1 |
| de Jong, M | 1 |
| Vujaskovic, Z | 1 |
| Thrasher, BA | 1 |
| Jackson, IL | 1 |
| Brizel, MB | 1 |
| Brizel, DM | 1 |
| Uma Devi, P | 1 |
| Navalkha, PL | 1 |
| Kumar, S | 1 |
| Jagetia, GC | 1 |
| Surana, M | 1 |
| Gupta, S | 1 |
| Pareek, BP | 1 |
| Yuhas, JM | 1 |
| Culo, F | 1 |
| Twentyman, PR | 1 |
| Ikebuchi, M | 1 |
| Shinohara, S | 1 |
| Kimura, H | 1 |
| Morimoto, K | 1 |
| Shima, A | 1 |
| Aoyama, T | 1 |
| Donaldson, SS | 1 |
| Moskowitz, PS | 1 |
| Evans, JW | 1 |
| Fajardo, LF | 1 |
| Fichtner, I | 1 |
| Lemm, M | 1 |
| Becker, M | 1 |
| Berthold, F | 1 |
| Inano, H | 1 |
| Onoda, M | 1 |
| Suzuki, K | 1 |
| Kobayashi, H | 1 |
| Wakabayashi, K | 1 |
| Herman, EH | 1 |
| Zhang, J | 1 |
| Chadwick, DP | 1 |
| Ferrans, VJ | 1 |
| Joshi, U | 1 |
| Raza, SK | 1 |
| Lakshmana Rao, PV | 1 |
| Malhotra, RC | 1 |
| Jaiswal, DK | 1 |
| Jahnukainen, K | 1 |
| Jahnukainen, T | 1 |
| Salmi, TT | 1 |
| Svechnikov, K | 1 |
| Eksborg, S | 1 |
| Söder, O | 1 |
| Gralla, EJ | 1 |
| Sabo, JP | 1 |
| Hayden, DW | 1 |
| Yochmowitz, MG | 1 |
| Mattsson, JL | 1 |
| Baker, WH | 1 |
| Nold, JB | 1 |
| Patchen, ML | 1 |
| Jackson, WE | 1 |
| Landauer, MR | 1 |
| Davis, HD | 1 |
| Dominitz, JA | 1 |
| Weiss, JF | 2 |
| Kuna, P | 1 |
| Dostál, M | 1 |
| Neruda, O | 1 |
| Petýrek, P | 1 |
| Svoboda, V | 1 |
| Resl, M | 1 |
| Prouza, Z | 1 |
| Hermanská, Z | 1 |
| Spurný, F | 1 |
| Listík, E | 1 |
| Palmer, TE | 1 |
| Glaza, SM | 1 |
| Dickie, BC | 1 |
| Weltman, RH | 1 |
| Greenspun, KS | 1 |
| Bogo, V | 1 |
| Jacobs, AJ | 1 |
| Bhartiya, HC | 1 |
1 trial available for amifostine anhydrous and Body Weight
| Article | Year |
|---|---|
Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686).
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Body Weight | 2003 |
30 other studies available for amifostine anhydrous and Body Weight
| Article | Year |
|---|---|
In Vivo Radioprotective Activity of Cell-Permeable Bifunctional Antioxidant Enzyme GST-TAT-SOD against Whole-Body Ionizing Irradiation in Mice.
Topics: Amifostine; Animals; Antioxidants; Body Weight; Glutathione Transferase; Liver; Male; Mice; Radiatio | 2017 |
Protective effect of amifostine on high-dose methotrexate-induced small intestinal mucositis in mice.
Topics: Amifostine; Animals; Body Weight; Female; Immunosuppressive Agents; Intestine, Small; Leucovorin; Ma | 2013 |
The acute-phase protein alpha2-macroglobulin plays an important role in radioprotection in the rat.
Topics: alpha-Macroglobulins; Amifostine; Animals; Blotting, Western; Body Weight; Electrophoresis, Polyacry | 2009 |
DRDE-07 and its analogues as promising cytoprotectants to nitrogen mustard (HN-2)--an alkylating anticancer and chemical warfare agent.
Topics: Amifostine; Animals; Antidotes; Antineoplastic Agents, Alkylating; Body Weight; Chemical Warfare Age | 2009 |
The radioprotective effect of alpha2-macroglobulin: a morphological study of rat liver.
Topics: alpha-Macroglobulins; Amifostine; Animals; Body Weight; Liver; Organ Size; Radiation-Protective Agen | 2009 |
Ameliorative effect of DRDE 07 and its analogues on the systemic toxicity of sulphur mustard and nitrogen mustard in rabbit.
Topics: Administration, Cutaneous; Amifostine; Animals; Antidotes; Body Weight; Chemical Warfare Agents; Dos | 2010 |
Comparative toxic effect of nitrogen mustards (HN-1, HN-2, and HN-3) and sulfur mustard on hematological and biochemical variables and their protection by DRDE-07 and its analogues.
Topics: Alkaline Phosphatase; Amifostine; Animals; Body Weight; Female; Lethal Dose 50; Leukocyte Count; Mec | 2010 |
Prophylactic efficacy of combination of DRDE-07 and its analogues with amifostine against sulphur mustard induced systemic toxicity.
Topics: Administration, Cutaneous; Administration, Oral; Amifostine; Animals; Body Weight; Chemical Warfare | 2010 |
Oxidative stress and inflammation contribute to lung toxicity after a common breast cancer chemotherapy regimen.
Topics: Amifostine; Animals; Antineoplastic Agents, Alkylating; Antioxidants; Blood Cell Count; Body Weight; | 2002 |
Amifostine protection against doxorubicin cardiotoxicity in rats.
Topics: Aconitine; Amifostine; Animals; Ascitic Fluid; Body Weight; Cardiac Tamponade; Cardiomyopathies; Dox | 2004 |
Combinations of radioprotectants spare radiation-induced damage to the physis.
Topics: Amifostine; Animals; Body Weight; Bone Density; Bone Development; Drug Therapy, Combination; Femur; | 2004 |
Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate.
Topics: Amifostine; Animals; Body Weight; Creatinine; Kidney; Lysine; Male; Neoplasms; Octreotide; Organomet | 2007 |
Radioprotective effects of amifostine on acute and chronic esophageal injury in rodents.
Topics: Acute Disease; Amifostine; Animals; Antigens, Neoplasm; Body Weight; Chronic Disease; Drug Evaluatio | 2007 |
Studies on toxic effect of WR-2721 in mouse.
Topics: Amifostine; Animals; Body Weight; Erythrocyte Count; Leukocyte Count; Lymphocytes; Mice; Organothiop | 1984 |
Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum(II) by WR-2721 without altering its antitumor properties.
Topics: Amifostine; Animals; Blood Urea Nitrogen; Body Weight; Cisplatin; Dose-Response Relationship, Drug; | 1980 |
Modification of tumour and host response to cyclophosphamide by misonidazole and by WR 2721.
Topics: Amifostine; Animals; Body Weight; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Therapy, | 1981 |
Effects of daily treatment with a radioprotector WR-2721 on Ehrlich's ascites tumors in mice : suppression of tumor cell growth and earlier death of tumor-bearing mice.
Topics: Amifostine; Animals; Body Weight; Carcinoma, Ehrlich Tumor; Female; Mice; Mice, Inbred Strains; Orga | 1981 |
Protection from radiation nephropathy by WR-2721.
Topics: Amifostine; Animals; Blood Urea Nitrogen; Body Weight; Dose-Response Relationship, Radiation; Female | 1984 |
Effects of amifostine (WR-2721, ethyol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas.
Topics: Amifostine; Animals; Antineoplastic Agents; Blood Platelets; Body Weight; Disease Models, Animal; Fe | 1997 |
Inhibitory effects of WR-2721 and cysteamine on tumor initiation in mammary glands of pregnant rats by radiation.
Topics: Adenocarcinoma; Amifostine; Animals; Body Weight; Cysteamine; Dose-Response Relationship, Radiation; | 2000 |
Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats.
Topics: Amifostine; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Body Weight; Doxorubicin; H | 2000 |
Prophylactic efficacy of amifostine and its analogues against sulphur mustard toxicity.
Topics: Administration, Oral; Amifostine; Animals; Body Weight; Dermatologic Agents; DNA Fragmentation; Fema | 2001 |
Amifostine protects against early but not late toxic effects of doxorubicin in infant rats.
Topics: Age Factors; Alopecia; Amifostine; Animals; Animals, Suckling; Antibiotics, Antineoplastic; Body Wei | 2001 |
The effect of selected drugs on first-stage radioemesis in beagle dogs.
Topics: Amifostine; Amphetamine; Animals; Antiemetics; Body Weight; Chlorpromazine; Dimenhydrinate; Diphenhy | 1979 |
Histopathologic effects of soluble glucan and WR-2721, independently and combined in C3H/HeN mice.
Topics: Amifostine; Animals; Body Weight; Drug Synergism; Female; Glucans; Hematopoietic Stem Cells; Kidney; | 1992 |
Long-term effects of radioprotector WR-2721 on locomotor activity and body weight of mice following exposure to ionizing radiation.
Topics: Amifostine; Animals; Body Weight; Dose-Response Relationship, Drug; Male; Mice; Motor Activity; Orga | 1988 |
[Radioprotective effect of gammaphos (WR-2721) and cystamine in the whole-body irradiation of mice using fission neutrons].
Topics: Amifostine; Animals; Body Weight; Bone Marrow; Cystamine; Female; Leukocyte Count; Mice; Neutrons; O | 1988 |
Toxicity studies on the radioprotective agent WR-2721 in CDF1 mice and beagle dogs.
Topics: Amifostine; Animals; Body Weight; Dogs; Dose-Response Relationship, Drug; Female; Kidney; Male; Mice | 1985 |
Behavioral toxicity and efficacy of WR-2721 as a radioprotectant.
Topics: Amifostine; Animals; Body Weight; Cobalt Radioisotopes; Gamma Rays; Male; Motor Activity; Organothio | 1985 |
Inhibition of reduction in the testicular weight by WR-2721 in relation to the body weight after whole-body gamma irradiation.
Topics: Amifostine; Animals; Body Weight; Dose-Response Relationship, Radiation; Gamma Rays; Male; Mice; Org | 1986 |